Leif Stenke

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

* specialist i invärtesmedicin och hematologi, docent vid KI. Han är
biträdande programdirektör för Socialstyrelsens Kunskapscentrum för
strålningsmedicin vid katastrofer (KcRN) som är en beredskapsfunktion
vid Centrum för strålningsmedicin.
* medlem i Socialstyrelsens medicinska expertgrupp för radiologiska och
nukleära händelser (RN-MeG). Han är också ledamot i Karolinska
Universitetssjukhusets strålskyddskommitté.

Forskningsbeskrivning

Stenkes forskning är inriktad mot studier av normal och förändrad blod-
och benmärgsfunktion vid sjukdomar och skador. Speciellt intresse riktas mot
myeloiska leukemier och inverkan av olika läkemedel och andra cellhämmande
agens, såsom joniserande strålning, på blodbildningen. Benmärgen,
kroppens ”blodfabrik”, är vårt känsligaste organ vad gäller effekt av
joniserande strålning. Om en människa utsätts för en hög stråldos är
överlevnadschansen därför vanligen beroende på omfattning och varaktighet
av det så kallade hematopoetiska syndromet, dvs graden av hämning av blod
och benmärg. Stenkes forskning syftar bl a till att förbättra kunskapen om
de cellulära och molekylära mekanismer som styr hur cellerna förökar sig
och hur de reparerar sina skador. Man studerar i detta sammanhang även
leukemiceller och hur de påverkas av olika typer av cellhämmande terapier.
Studierna är delvis av grundforskningskaraktär, med avsikten att t ex
molekylära upptäckter och fynd i samband med leukemibehandling i
förlängningen också kan leda till nya behandlingsmöjligheter för
benmärgsskadade patienter i samband med en strålningsolycka.

Artiklar

Article: AMERICAN JOURNAL OF HEMATOLOGY. 2022;97(4):421-430

Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study.

Dahlén T; Edgren G; Ljungman P; Flygt H; Richter J; Olsson-Strömberg U; Wadenvik H; Dreimane A; Myhr-Eriksson K; Zhao J; Själander A; Höglund M; Stenke L
Article: JOURNAL OF RADIOLOGICAL PROTECTION. 2022;42(1):014004

The acute radiation syndrome-need for updated medical guidelines.

Stenke L; Hedman C; Lagergren Lindberg M; Lindberg K; Valentin J
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2021;107(6):617-623

Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study.

Flygt H; Söderlund S; Stentoft J; Richter J; Koskenvesa P; Mustjoki S; Majeed W; Lübking A; Dreimane A; Markevärn B; Stenke L; Myhr Eriksson K; Gjertsen BT; Gedde-Dahl T; Dimitrijevic A; Udby L; Olsson-Strömberg U; Hjorth-Hansen H
Article: CELL DEATH & DISEASE. 2021;12(10):875

Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells.

Malyukova A; Ujvari D; Yektaei-Karin E; Zovko A; Madapura HS; Keszei M; Nagy N; Lotfi K; Björn N; Wallvik J; Tamai M; Nguyen TTT; Akahane K; Inukai T; Stenke L; Salamon D
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;193(5):915-921

Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.

Flygt H; Sandin F; Dahlén T; Dremaine A; Lübking A; Markevärn B; Myhr-Eriksson K; Olsson K; Olsson-Strömberg U; Själander A; Söderlund S; Wennström L; Wadenvik H; Stenke L; Höglund M; Richter J
Article: CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 2020;29(1):151-156

Increased Risk of Chronic Myeloid Leukemia Following Gastric Conditions Indicating Helicobacter pylori Infection: A Case-Control Study.

Larfors G; Richter J; Själander A; Stenke L; Höglund M
Article: BONE MARROW TRANSPLANTATION. 2019;54(11):1764-1774

Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry.

Lübking A; Dreimane A; Sandin F; Isaksson C; Märkevärn B; Brune M; Ljungman P; Lenhoff S; Stenke L; Höglund M; Richter J; Olsson-Strömberg U
Article: ONCOIMMUNOLOGY. 2019;8(9):e1638210

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line.

Kreutzman A; Yadav B; Brummendorf TH; Gjertsen BT; Hee Lee M; Janssen J; Kasanen T; Koskenvesa P; Lotfi K; Markevärn B; Olsson-Strömberg U; Stentoft J; Stenke L; Söderlund S; Udby L; Richter J; Hjorth-Hansen H; Mustjoki S
Article: APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2019;17(4):555-567

Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia.

Hirt C; Iannazzo S; Chiroli S; McGarry LJ; le Coutre P; Stenke L; Dahlén T; Lipton JH
Article: ONCOLOGY REPORTS. 2018;40(2):902-908

Montelukast, a cysteinyl leukotriene receptor antagonist, inhibits the growth of chronic myeloid leukemia cells through apoptosis.

Zovko A; Yektaei-Karin E; Salamon D; Nilsson A; Wallvik J; Stenke L
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2018;498(3):502-508

Interferon γ is a strong, STAT1-dependent direct inducer of BCL6 expression in multiple myeloma cells.

Ujvari D; Nagy N; Madapura HS; Kallas T; Kröhnke MCL; Stenke L; Klein E; Salamon D
Article: LAKARTIDNINGEN. 2017;114:ER3M

[Chronic myeloid leukemia – a model disease for targeted therapy].

Richter J; Stenke L
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2017;490(2):378-384

Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34+CD38- stem and progenitor cells in chronic myeloid leukemia.

Dolinska M; Piccini A; Wong WM; Gelali E; Johansson A-S; Klang J; Xiao P; Yektaei-Karin E; Strömberg UO; Mustjoki S; Stenke L; Ekblom M; Qian H
Article: ONCOGENE. 2017;36(32):4619-4628

Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells.

Madapura HS; Nagy N; Ujvari D; Kallas T; Kröhnke MCL; Amu S; Björkholm M; Stenke L; Mandal PK; McMurray JS; Keszei M; Westerberg LS; Cheng H; Xue F; Klein G; Klein E; Salamon D
Article: LEUKEMIA & LYMPHOMA. 2017;58(8):1903-1913

Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia.

Yektaei-Karin E; Zovko A; Nilsson A; Näsman-Glaser B; Kanter L; Rådmark O; Wallvik J; Ekblom M; Dolinska M; Qian H; Stenke L
Article: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2017;143(8):1543-1554

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.

Rajala HLM; Missiry ME; Ruusila A; Koskenvesa P; Brümmendorf TH; Gjertsen BT; Janssen J; Lotfi K; Markevärn B; Olsson-Strömberg U; Stenke L; Stentoft J; Richter J; Hjorth-Hansen H; Kreutzman A; Mustjoki S
Article: HAEMATOLOGICA. 2017;102(8):1361-1367

Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib.

Gullaksen S-E; Skavland J; Gavasso S; Tosevski V; Warzocha K; Dumrese C; Ferrant A; Gedde-Dahl T; Hellmann A; Janssen J; Labar B; Lang A; Majeed W; Mihaylov G; Stentoft J; Stenke L; Thaler J; Thielen N; Verhoef G; Voglova J; Ossenkoppele G; Hochhaus A; Hjorth-Hansen H; Mustjoki S; Sopper S; Giles F; Porkka K; Wolf D; Gjertsen BT
Article: LEUKEMIA. 2017;31(5):1108-1116

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Ilander M; Olsson-Strömberg U; Schlums H; Guilhot J; Brück O; Lähteenmäki H; Kasanen T; Koskenvesa P; Söderlund S; Höglund M; Markevärn B; Själander A; Lotfi K; Dreimane A; Lübking A; Holm E; Björeman M; Lehmann S; Stenke L; Ohm L; Gedde-Dahl T; Majeed W; Ehrencrona H; Koskela S; Saussele S; Mahon F-X; Porkka K; Hjorth-Hansen H; Bryceson YT; Richter J; Mustjoki S
Article: BLOOD. 2017;129(17):2384-2394

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.

Warfvinge R; Geironson L; Sommarin MNE; Lang S; Karlsson C; Roschupkina T; Stenke L; Stentoft J; Olsson-Strömberg U; Hjorth-Hansen H; Mustjoki S; Soneji S; Richter J; Karlsson G
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2017;98(4):398-406

The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia.

Larfors G; Sandin F; Richter J; Själander A; Stenke L; Lambe M; Höglund M
Article: PLOS ONE. 2017;12(1):e0171041

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.

El Missiry M; Hjorth-Hansen H; Richter J; Olson-Strömberg U; Stenke L; Porkka K; Kreutzman A; Mustjoki S
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2017;98(1):57-66

Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register.

Söderlund S; Dahlén T; Sandin F; Olsson-Strömberg U; Creignou M; Dreimane A; Lübking A; Markevärn B; Själander A; Wadenvik H; Stenke L; Richter J; Höglund M
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2016;97(4):387-392

Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.

Gunnarsson N; Sandin F; Höglund M; Stenke L; Björkholm M; Lambe M; Olsson-Strömberg U; Richter J; Själander A
Article: LEUKEMIA. 2016;30(9):1853-1860

Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients.

Hjorth-Hansen H; Stentoft J; Richter J; Koskenvesa P; Höglund M; Dreimane A; Porkka K; Gedde-Dahl T; Gjertsen BT; Gruber FX; Stenke L; Eriksson KM; Markevärn B; Lübking A; Vestergaard H; Udby L; Bjerrum OW; Persson I; Mustjoki S; Olsson-Strömberg U
Article: CLINICAL CANCER RESEARCH. 2016;22(16):4030-4038

Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.

Thielen N; Richter J; Baldauf M; Barbany G; Fioretos T; Giles F; Gjertsen B-T; Hochhaus A; Schuurhuis GJ; Sopper S; Stenke L; Thunberg S; Wolf D; Ossenkoppele G; Porkka K; Janssen J; Mustjoki S
Article: ANNALS OF INTERNAL MEDICINE. 2016;165(3):161-166

Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.

Dahlén T; Edgren G; Lambe M; Höglund M; Björkholm M; Sandin F; Själander A; Richter J; Olsson-Strömberg U; Ohm L; Bäck M; Stenke L; Swedish CML Group and the Swedish CML Register Gro
Article: LEUKEMIA. 2016;30(7):1562-1567

Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.

Gunnarsson N; Höglund M; Stenke L; Wållberg-Jonsson S; Sandin F; Björkholm M; Dreimane A; Lambe M; Markevärn B; Olsson-Strömberg U; Wadenvik H; Richter J; Själander A
Article: LANCET ONCOLOGY. 2016;17(5):612-621

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.

Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW; EPIC investigators
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2015;169(5):683-688

Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.

Gunnarsson N; Stenke L; Höglund M; Sandin F; Björkholm M; Dreimane A; Lambe M; Markevärn B; Olsson-Strömberg U; Richter J; Wadenvik H; Wallvik J; Själander A
Article: LEUKEMIA & LYMPHOMA. 2015;56(5):1385-1391

Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib.

Ohm L; Lundqvist A; Dickman P; Höglund M; Persson U; Stenke L; Carlsson KS; Björkholm M
Article: MOLECULAR CANCER THERAPEUTICS. 2015;14(5):1181-1191

The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses.

Christiansson L; Söderlund S; Mangsbo S; Hjorth-Hansen H; Höglund M; Markevärn B; Richter J; Stenke L; Mustjoki S; Loskog A; Olsson-Strömberg U
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2015;94(3):243-250

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).

Hjorth-Hansen H; Stenke L; Söderlund S; Dreimane A; Ehrencrona H; Gedde-Dahl T; Gjertsen BT; Höglund M; Koskenvesa P; Lotfi K; Majeed W; Markevärn B; Ohm L; Olsson-Strömberg U; Remes K; Suominen M; Simonsson B; Porkka K; Mustjoki S; Richter J; Nordic CML Study Group
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2015;21(3):559-564

Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.

Othus M; Appelbaum FR; Petersdorf SH; Kopecky KJ; Slovak M; Nevill T; Brandwein J; Larson RA; Stiff PJ; Walter RB; Tallman MS; Stenke L; Erba HP
Article: CANCER CELL. 2014;26(3):428-442

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Zabriskie MS; Eide CA; Tantravahi SK; Vellore NA; Estrada J; Nicolini FE; Khoury HJ; Larson RA; Konopleva M; Cortes JE; Kantarjian H; Jabbour EJ; Kornblau SM; Lipton JH; Rea D; Stenke L; Barbany G; Lange T; Hernández-Boluda J-C; Ossenkoppele GJ; Press RD; Chuah C; Goldberg SL; Wetzler M; Mahon F-X; Etienne G; Baccarani M; Soverini S; Rosti G; Rousselot P; Friedman R; Deininger M; Reynolds KR; Heaton WL; Eiring AM; Pomicter AD; Khorashad JS; Kelley TW; Baron R; Druker BJ; Deininger MW; O'Hare T
Article: CANCER. 2013;119(16):3076-3083

Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity.

Patel C; Stenke L; Varma S; Lindberg ML; Björkholm M; Sjöberg J; Viktorsson K; Lewensohn R; Landgren O; Gottesman MM; Gillet J-P
Article: BLOOD. 2013;122(7):1284-1292

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.

Höglund M; Sandin F; Hellström K; Björeman M; Björkholm M; Brune M; Dreimane A; Ekblom M; Lehmann S; Ljungman P; Malm C; Markevärn B; Myhr-Eriksson K; Ohm L; Olsson-Strömberg U; Själander A; Wadenvik H; Simonsson B; Stenke L; Richter J
Article: LEUKEMIA. 2013;27(7):1520-1526

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.

Mustjoki S; Richter J; Barbany G; Ehrencrona H; Fioretos T; Gedde-Dahl T; Gjertsen BT; Hovland R; Hernesniemi S; Josefsen D; Koskenvesa P; Dybedal I; Markevärn B; Olofsson T; Olsson-Strömberg U; Rapakko K; Thunberg S; Stenke L; Simonsson B; Porkka K; Hjorth-Hansen H; Nordic CML Study Group (NCMLSG)
Article: BLOOD. 2013;121(24):4854-4860

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

Petersdorf SH; Kopecky KJ; Slovak M; Willman C; Nevill T; Brandwein J; Larson RA; Erba HP; Stiff PJ; Stuart RK; Walter RB; Tallman MS; Stenke L; Appelbaum FR
Article: EXPERIMENTAL HEMATOLOGY. 2012;40(11):906-913

Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.

Kreutzman A; Jaatinen T; Greco D; Vakkila E; Richter J; Ekblom M; Hjorth-Hansen H; Stenke L; Melo T; Paquette R; Seggewiss-Bernhardt R; Guerci-Bresler A; Talbot A; Cayuela JM; Mahon F-X; Porkka K; Lipton J; Partanen J; Rousselot P; Mustjoki S
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2012;87(8):760-765

Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome.

Ohm L; Arvidsson I; Barbany G; Hast R; Stenke L
Article: LEUKEMIA. 2011;25(10):1587-1597

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.

Kreutzman A; Ladell K; Koechel C; Gostick E; Ekblom M; Stenke L; Melo T; Einsele H; Porkka K; Price DA; Mustjoki S; Seggewiss R
Article: LANCET ONCOLOGY. 2011;12(9):841-851

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.

Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh Y-T; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Article: BLOOD. 2010;116(5):772-782

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

Kreutzman A; Juvonen V; Kairisto V; Ekblom M; Stenke L; Seggewiss R; Porkka K; Mustjoki S
Article: LEUKEMIA. 2009;23(8):1398-1405

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.

Mustjoki S; Ekblom M; Arstila TP; Dybedal I; Epling-Burnette PK; Guilhot F; Hjorth-Hansen H; Höglund M; Kovanen P; Laurinolli T; Liesveld J; Paquette R; Pinilla-Ibarz J; Rauhala A; Shah N; Simonsson B; Sinisalo M; Steegmann JL; Stenke L; Porkka K
Article: EXPERIMENTAL HEMATOLOGY. 2009;37(6):755-766

Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML.

Haag P; Viktorsson K; Lindberg ML; Kanter L; Lewensohn R; Stenke L
Article: JOURNAL OF PROTEOME RESEARCH. 2008;7(6):2332-2341

Proteomic data analysis workflow for discovery of candidate biomarker peaks predictive of clinical outcome for patients with acute myeloid leukemia.

Forshed J; Pernemalm M; Tan CS; Lindberg M; Kanter L; Pawitan Y; Lewensohn R; Stenke L; Lehtiö J
Article: LEUKEMIA & LYMPHOMA. 2006;47(9):1768-1773

Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase.

Olsson-Strömberg U; Höglund M; Björkholm M; Braide I; Carlson K; Gahrton G; Grimfors G; Hast R; Lerner R; Linder O; Ljungman P; Löfvenberg E; Malm C; Nilsson P-G; Paul C; Rödjer S; Stenke L; Tidefeldt U; Turesson I; Uden A-M; Wahlin A; Vilen L; Winqvist I; Zettervall O; Oberg G; Simonsson B
Article: ACTA HAEMATOLOGICA. 2005;113(3):155-162

Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up.

Simonsson B; Oberg G; Bjoreman M; Bjorkholm M; Carneskog J; Karlsson K; Gahrton G; Grimfors G; Hast R; Karle H; Linder O; Ljungman P; Nielsen JL; Nilsson J; Lofvenberg E; Malm C; Olsson K; Olsson-Stromberg U; Paul C; Stenke L; Stentoft J; Turesson I; Udén A-M; Wahlin A; Vilén L; Weis-Bjerrum O
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2004;124(6):739-745

Abnormal LTC4 synthase RNA degradation in neutrophils from CML patients.

Roos C; Sjölinder M; Stenke L; Tornhamre S
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2004;350(2):114-124

Efficacy and safety of low-dose aspirin in polycythemia vera.

Landolfi R; Marchioli R; Kutti J; Gisslinger H; Tognoni G; Patrono C; Barbui T; European Collaboration on Low-Dose Aspirin in Poly
Article: LEUKEMIA RESEARCH. 2003;27(4):323-328

A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.

Gruber A; Björkholm M; Brinch L; Evensen S; Gustavsson B; Hedenus M; Juliusson G; Löfvenberg E; Nesthus I; Simonsson B; Sjo M; Stenke L; Tangen JM; Tidefelt U; Udén A-M; Paul C; Liliemark J
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2003;348(11):994-1004

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

O'Brien SG; Guilhot F; Larson RA; Gathmann I; Baccarani M; Cervantes F; Cornelissen JJ; Fischer T; Hochhaus A; Hughes T; Lechner K; Nielsen JL; Rousselot P; Reiffers J; Saglio G; Shepherd J; Simonsson B; Gratwohl A; Goldman JM; Kantarjian H; Taylor K; Verhoef G; Bolton AE; Capdeville R; Druker BJ; IRIS Investigators
Article: EXPERIMENTAL HEMATOLOGY. 2003;31(2):122-130

Inverse relationship between myeloid maturation and leukotriene C4 synthase expression in normal and leukemic myelopoiesis-consistent overexpression of the enzyme in myeloid cells from patients with chronic myeloid leukemia.

Tornhamre S; Stenke L; Granzelius A; Sjölinder M; Näsman-Glaser B; Roos C; Widell S; Lindgren JA
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2002;118(4):1048-1054

Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.

Axdorph U; Stenke L; Grimfors G; Carneskog J; Hansen J; Linder O; Ljungman P; Löfvenberg E; Malm C; Simonsson B; Turesson I; Vilén L; Udén A-M; Björkholm M; Swedish CML Group
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2002;118(3):748-754

High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia.

Hallböök H; Simonsson B; Ahlgren T; Björkholm M; Carneskog J; Grimfors G; Hast R; Karlsson K; Kimby E; Lerner R; Linder O; Linderholm M; Löfvenberg E; Malm C; Nilsson P-G; Paul C; Stenke L; Stockelberg D; Tidefelt U; Turesson I; Uden-Blome A-M; Vilen L; Wahlin A; Winquist I; Smedmyr B
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2002;68(6):376-381

Long-term follow-up of patients >or=60 yr old with acute myeloid leukaemia treated with intensive chemotherapy.

Oberg G; Killander A; Björeman M; Gahrton G; Grimfors G; Gruber A; Hast R; Lerner R; Liliemark J; Mattson S; Paul C; Simonsson B; Stalfelt A-M; Stenke L; Tidefelt U; Udén A-M; Björkholm M; LGMS
Article: LAKARTIDNINGEN. 2002;99(13):1453-1455

[Management of radiation injuries--new organization, new guidelines].

Lewensohn R; Joussineau S; Stenke L
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2002;68(3):180-186

Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.

Wallvik J; Stenke L; Bernell P; Nordahl G; Hippe E; Hast R
Article: LEUKEMIA RESEARCH. 2001;25(1):13-18

Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment.

Hast R; Wallvik J; Folin A; Bernell P; Stenke L
Article: JOURNAL OF CLINICAL ONCOLOGY. 2000;18(9):1837-1844

P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.

Tidefelt U; Liliemark J; Gruber A; Liliemark E; Sundman-Engberg B; Juliusson G; Stenke L; Elmhorn-Rosenborg A; Möllgård L; Lehman S; Xu D; Covelli A; Gustavsson B; Paul C
Article: BLOOD. 2000;95(4):1456-1464

Aberrant expression of active leukotriene C(4) synthase in CD16(+) neutrophils from patients with chronic myeloid leukemia.

Sjölinder M; Stenke L; Näsman-Glaser B; Widell S; Doucet J; Jakobsson PJ; Lindgren JA
Article: JOURNAL OF LEUKOCYTE BIOLOGY. 1998;64(2):228-234

Expression of mRNA encoding neurotrophins and neurotrophin receptors in human granulocytes and bone marrow cells--enhanced neurotrophin-4 expression induced by LTB4.

Laurenzi MA; Beccari T; Stenke L; Sjölinder M; Stinchi S; Lindgren JA
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1998;101(4):728-736

Novel enzymatic abnormalities in AML and CML in blast crisis: elevated leucocyte leukotriene C4 synthase activity paralleled by deficient leukotriene biosynthesis from endogenous substrate.

Stenke L; Sjölinder M; Miale TD; Lindgren JA
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1997;58(4):241-245

Differences in cell lineage involvement between MDS-AML and de novo AML studied by fluorescence in situ hybridization in combination with morphology.

Bernell P; Arvidsson I; Hast R; Jacobsson B; Stenke L
Article: LEUKEMIA RESEARCH. 1996;20(8):693-699

A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes.

Bernell P; Stenke L; Wallvik J; Hippe E; Hast R
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1995;55(1):19-23

Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia. A randomized comparison.

Björkholm M; Liliemark J; Gahrton G; Grimfors G; Gruber A; Hast R; Juliusson G; Järnmark M; Killander A; Kimby E
Visa fler

Alla övriga publikationer

Letter: LEUKEMIA. 2021;35(8):2416-2418

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI.

Richter J; Lübking A; Söderlund S; Lotfi K; Markevärn B; Själander A; Stenke L; Deneberg S; Ahlstrand E; Myhr-Eriksson K; Panayiotidis P; Gedde-Dahl T; Žáčková D; Mayer J; Olsson-Strömberg U; Mahon F-X; Saussele S; Hjorth-Hansen H; Koskenvesa P
Editorial comment: JACC: CARDIOONCOLOGY. 2020;2(1):123-126

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia.

Carracedo M; Stenke L; Franco-Cereceda A; Bäck M
Published conference paper: RADIATION PROTECTION DOSIMETRY. 2018;182(1):80-84

COORDINATION OF MANAGEMENT OF THE ACUTE RADIATION SYNDROME.

Stenke L; Lindberg K; Lagergren Lindberg M; Lewensohn R; Valentin J; Powles R; Dainiak N
Letter: LEUKEMIA. 2017;31(8):1825-1827

No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden.

Gunnarsson N; Höglund M; Stenke L; Sandin F; Björkholm M; Dreimane A; Lambe M; Markevärn B; Olsson-Strömberg U; Wadenvik H; Richter J; Själander A
Published conference paper: RADIATION PROTECTION DOSIMETRY. 2016;171(1):134-138

Lessons Learnt from the Fukushima Accident-A Swedish Medical Preparedness Perspective.

Stenke L; von Schreeb J; Simonsson M; Johansson J; Postgård P; Sigurdsson S; Ljungquist Å; Lagergren Lindberg M
Published conference paper: RADIATION PROTECTION DOSIMETRY. 2016;171(1):144-155

Using the Grade Approach to Support the Development of Recommendations for Public Health Interventions in Radiation Emergencies.

Carr Z; Clarke M; Akl EA; Schneider R; Murith C; Li C; Parrish-Sprowl J; Stenke L; Cui-Ping L; Bertrand S; Miller C
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(25):2821-2823

Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?

Richter J; Söderlund S; Lübking A; Dreimane A; Lotfi K; Markevärn B; Själander A; Saussele S; Olsson-Strömberg U; Stenke L
Review: DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS. 2011;5(3):202-212

First global consensus for evidence-based management of the hematopoietic syndrome resulting from exposure to ionizing radiation.

Dainiak N; Gent RN; Carr Z; Schneider R; Bader J; Buglova E; Chao N; Coleman CN; Ganser A; Gorin C; Hauer-Jensen M; Huff LA; Lillis-Hearne P; Maekawa K; Nemhauser J; Powles R; Schünemann H; Shapiro A; Stenke L; Valverde N; Weinstock D; White D; Albanese J; Meineke V
Review: DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS. 2011;5(3):183-201

Literature review and global consensus on management of acute radiation syndrome affecting nonhematopoietic organ systems.

Dainiak N; Gent RN; Carr Z; Schneider R; Bader J; Buglova E; Chao N; Coleman CN; Ganser A; Gorin C; Hauer-Jensen M; Huff LA; Lillis-Hearne P; Maekawa K; Nemhauser J; Powles R; Schünemann H; Shapiro A; Stenke L; Valverde N; Weinstock D; White D; Albanese J; Meineke V
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2010;8(5):134-135

The DNA glycosylase Myh1 is stabilized by cisplatin and inhibition of Myh1 expression increases cisplatin-induced apoptotic signaling in lung carcinoma cells

Viktorsson K; Efazat G; Haag P; Zong D; Stenke L; Sunnerhagen P; Lewensohn R
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2010;8(5):57

Cytotoxicity and cell death signaling in stem cell like AML cells

Haag P; Lindberg ML; Zong D; Kanter L; Lewensohn R; Stenke L; Viktorsson K
Letter: ANNALS OF HEMATOLOGY. 2009;88(2):173-175

Chronic myeloid leukemia presenting late in pregnancy. Report of a case and a questionnaire reflecting diversity in management options.

Björkholm M; Ohm L; Stenke L
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2008;142(6):992-995

Clinical imatinib mesylate treatment induces early normalisation of aberrant neutrophil leukotriene C4 synthase expression and activity in chronic myeloid leukaemia.

Roos C; Stenke L; Ohm L; Widell S; Kumlin M; Lindgren JA; Tornhamre S
Letter: LEUKEMIA. 2006;20(11):2057-2060

A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib.

Gruber FX; Hjorth-Hansen H; Mikkola I; Stenke L; Johansen T
Meeting abstract: BLOOD. 2005;106(11):222B

Gemtuzumab ozogamicin combined with hyper-CVAD in relapsed refractory CD33-positive acute lymphoblastic leukemia.

Stromberg O; Stenke L; Bernell P
Meeting abstract: BLOOD. 2005;106(11):566A

Quantitative analyses of BCR-ABL mutations associated with imatinib treatment in CML

Gruber F; Hansen HH; Olsen M; Eggen L; Skogen B; Gedde-Dahl T; Lundan T; Porkka K; Simonsson B; Markevdrn B; Wadenvik H; Stenke L
Review: LAKARTIDNINGEN. 2000;97(3):164-167

[Radioimmunotherapy is rapidly developing to clinically efficient therapy].

Stenke L; Lewensohn R; Carlsson J

Om mig

Forskningsbeskrivning

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI